Liraglutide as anti-obesity agent
:Obesity
:Phase 3
Obesity is an increasing global problem, which is associated with increased morbidity, including a significantly increased risk of developing type 2 diabetes. One of the main problems with existing obesity treatment is the sustainability of weight loss as many patients regain weight.
Liraglutide, Novo Nordisk’s once-daily, human GLP-1 analogue, has shown the potential in both preclinical studies as well as in non-diabetic human subjects to reduce food intake and induce weight loss.
- Company announcements
- Interim financial report for the period 1 January 2010 to 30 June 2010 (05 Aug 2010)
- Novo Nordisk re-initiates phase 3 development of liraglutide for obesity (22 Jun 2010)
- Novo Nordisk provides update on corporate strategy at its Capital Markets Day (26 Sep 2008)
- Read more company announcements
- Press releases
- New data demonstrate Victoza® (liraglutide) provided superior and sustained blood sugar control and weight reduction compared to Januvia® (sitagliptin) at 52 weeks (26 Jun 2010)
- Novo Nordisk partners with international scientific community for Victoza® cardiovascular outcomes trial (06 May 2010)
- Read more press releases
- Scientific abstracts
- Diabetes (2007)
- Diabetes Obesity and Metabolism (2008)
- Obesity (2007)
- Read more scientific abstracts
